Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170002/S059

RHA 2, RHA 3, RHA 4

Teoxane S.A. · Decision date Aug 31, 2026

FDA DECISIONP170002/S059

What did the FDA decide?

FDA records P170002/S059 as a supplement to PMA P170002, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 31, 2026.

FDA approval order statement

Approval for an alternative qualified laboratory for Biological Indicator release testing as part of receiving inspection
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Aug 31, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P170002/S059
Regulatory pathway
PMA supplement
Applicant
Teoxane S.A.
Product code
LMH
Decision code
OK30
Decision date
Aug 31, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Applicant
Teoxane S.A.
Product code
LMH
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P170002/S048 · Related supplement

    RHA Dynamic Volume, RHA4

  2. P170002/S051 · Related supplement

    RHA Redensity dermal filler

  3. P170002/S053 · Related supplement

    RHA Redensity Mepi (also called RHA1 Mepi), RHA2 Mepi, RHA3 Mepi, RHA Dynamic Volume (formerly called RHA4 Mepi)

  4. P170002/S054 · Related supplement

    RHA Redensity, RHA Redensity Mepi, RHA2 and RHA2 Mepi, RHA3 and RHA3 Mepi, RHA4 and RHA Dynamic Volume

  5. P170002/S050 · Related supplement

    RHA Redensity Eye Lido; RHA Redensity Eye

  6. P170002/S052 · Related supplement

    RHA Redensity, RHA Redensity Mepi

  7. P170002/S059 received

    Application receipt date recorded by FDA.

  8. P170002/S059 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P170002. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170002

Product / regulatory recordCompanyPathwayDecision dateSource
Teoxane S.A.PMA supplementSep 18, 2025FDA
Teoxane S.A.PMA supplementJan 14, 2026FDA
Teoxane S.A.PMA supplementMar 31, 2026FDA
Teoxane S.A.PMA supplementApr 1, 2026FDA
Teoxane S.A.PMA supplementApr 7, 2026FDA
Teoxane S.A.PMA supplementMay 12, 2026FDA
Teoxane S.A.PMA supplementJul 2, 2026FDA
RHA Kiss VolumeP170002/S055
Teoxane S.A.PMA supplementJul 27, 2026FDA
Teoxane S.A.PMA supplementAug 28, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Teoxane S.A.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Les Charmilles Rue De Lyon, 105, Geneva, 1203

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records